Perspective Therapeutics (CATX) vs Cypherpunk Technologies (CYPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cypherpunk Technologies (CYPH) has outperformed Perspective Therapeutics (CATX) over the past year, gaining 387.2% versus a loss of 29.1%. Over five years, CATX leads with a -60.3% price change compared with -90.3% for CYPH. Cypherpunk Technologies is the larger company by market cap ($280.7 million vs $276.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | CYPH |
|---|---|---|
| Share price | $2.43 | $2.61 |
| Market cap | $276.82M | $280.73M |
| 1-day change | -1.42% | -14.62% |
| YTD return | -10.55% | +162.93% |
| 1-year return | -29.11% | +387.22% |
| 5-year return | -60.32% | -90.32% |
| P/E ratio (TTM) | — | 4.13 |
| EPS (TTM) | $-1.33 | $0.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.16 | $4.19 |
| 52-week low | $1.96 | $0.393 |
| Distance from 52-week high | -60.63% | -37.83% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +406.80% | +88.10% |
| Average volume | 1.67M | 9.88M |
| Shares outstanding | 114.15M | 107.76M |
| Employees | 163 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CYPH has outperformed CATX by 416.3 percentage points over the past year.
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
About Cypherpunk Technologies
CYPH stock →Cypherpunk Technologies Inc., a privacy technology company, implements a digital asset strategy anchored by Zcash in the United States. The company is involved in identifying, developing, investing in, acquiring, and building privacy-enhancing technologies; and accumulating digital assets, such as ZCash.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
CATX vs CYPH FAQ
Which is bigger, Perspective Therapeutics or Cypherpunk Technologies?
Cypherpunk Technologies (CYPH) is larger, with a market capitalization of $280.73M compared with $276.82M for Perspective Therapeutics (CATX).
Which stock has performed better over the past year, CATX or CYPH?
CYPH returned +387.22% over the past 12 months, compared with -29.11% for CATX (price return, excluding dividends). Past performance does not predict future results.
Are Perspective Therapeutics and Cypherpunk Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.